Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab.

New study provides insights into the relationship between TP53, miR-34a, and NOTCH1 in CLL cells.

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis.

The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.

A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.

A mathematical model using pharmacodynamic parameters, including duration of hyperlymphocytosis, may help clinicians better predict patient responses to ibrutinib administered for chronic lymphocytic leukemia (CLL).

A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective.

As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.

Researchers believe that in their revised 4-factor model to predict patient outcomes in chronic lymphocytic leukemia (CLL), CD49d tops lactate dehydrogenase.

The findings support previous research suggesting that worse prognosis in patients with del(6q) is not solely a result of genomic instability or presence of multiple genetic alterations.

This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

Researchers of a new study explore what areas of chronic lymphocytic leukemia (CLL) treatment and care are important to patients and identify key areas for improvement.

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

Experts evaluate the value of BTK inhibitors in CLL treatment.

A post-hoc analysis showed that zanubrutinib resulted in fewer adverse events compared with ibrutinib.

It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly.

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this population.

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

In the realm of lymphoma and chronic lymphocytic leukemia (CLL), and of the treatments that address them, a global survey of nearly 7000 patients proves there’s a long way to go to eliminate cancer-related fatigue from their lives.

This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and overall survival.

Researchers have found that specific genetic markers may increase the risk of cardiovascular adverse effects in patients using Bruton’s tyrosine kinase (BTK) inhibitors.

A real-world report showed the safety and efficacy of zanubrutinib after a community oncology practice replaced ibrutinib with the newer Bruton tyrosine kinase inhibitor on its formulary.

An abstract presented at the 2024 American Society of Clinical Oncology annual meeting showed that patients treated with zanubrutinib or acalabrutinib had more favorable safety and efficacy outcomes.